Key result
Hyperlactatemia during cardiopulmonary bypass was independently associated with an increased risk of major postoperative morbidity (OR 2.9) but not mortality.
Why the study?
Does hyperlactatemia during cardiopulmonary bypass predict increased postoperative morbidity and mortality in adult patients undergoing cardiac surgery?
Population
470 adult patients undergoing cardiac surgery with cardiopulmonary bypass, mean age 64.5, 69% male, based in…
Comparison
Hyperlactatemia during cardiopulmonary bypass vs Patients without hyperlactatemia during…
Design
Cohort
Follow-up
postoperative hospital stay
Authors
Loading...
Hyperlactatemia during CPB may flag higher morbidity risk; hypothesis-generating and should not yet change practice.
Observational (n=470)
No
Does hyperlactatemia during cardiopulmonary bypass predict increased postoperative morbidity and mortality in adult patients undergoing cardiac surgery?
Odds Ratio: 2.9 (95% CI 1.03–8.5)
Absolute Event Rate: 33.3% vs 8.1%
Hyperlactatemia during cardiopulmonary bypass is primarily driven by insufficient oxygen delivery and prolonged bypass time, and serves as a marker for increased postoperative morbidity.
Ranucci et al. (2006) conducted an observational in Cardiac surgery (n=470). Hyperlactatemia during cardiopulmonary bypass vs. No hyperlactatemia was evaluated on Composite morbidity index (surgical reoperation, intra-aortic balloon pump, stroke, acute renal failure, or sepsis) (OR 2.9, 95% CI 1.03-8.5). Hyperlactatemia during cardiopulmonary bypass was independently associated with an increased risk of major postoperative morbidity (OR 2.9) but not mortality.